Peficitinib
CAS: 944118-01-8
Rif. 3D-UMB11801
1mg | Fuori produzione | ||
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
- 4-[(anti-5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
- stereoisomer of 4-[(5-Hydroxytricyclo[3.3.1.13,7]dec-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
- 4-[(trans-5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
- 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)amino]-, stereoisomer
Peficitinib is a selective inhibitor of the Janus kinase (JAK) family. It has been shown to inhibit the angiogenic process in vitro and in animal models, suggesting that peficitinib may be useful for the treatment of diseases with an underlying inflammatory component, such as rheumatoid arthritis and bowel disease. Peficitinib has also been shown to effectively reduce disease activity in patients with active rheumatoid arthritis. Peficitinib binds to and inhibits JAKs 1-3, which are involved in the inflammatory response.